PropThink: Keryx Conference Call Emphasizes Multiple Catalysts by Year’s End

[ACN Newswire] – By Jake KingKeryx BioPharmaceuticals (NASDAQ:KERX) updated investors Thursday morning on both its Zerenex development program and its 3Q financials, reiterating that pivotal Phase 3 data for the drug will … more

View todays social media effects on KERX

View the latest stocks trending across Twitter. Click to view dashboard